Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.820
+0.060 (2.17%)
Nov 28, 2025, 4:00 PM EST - Market closed
Fortress Biotech Employees
Fortress Biotech had 101 employees as of December 31, 2024. The number of employees decreased by 85 or -45.70% compared to the previous year.
Employees
101
Change (1Y)
-85
Growth (1Y)
-45.70%
Revenue / Employee
$616,861
Profits / Employee
-$52,832
Market Cap
87.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 101 | -85 | -45.70% |
| Dec 31, 2023 | 186 | -1 | -0.53% |
| Dec 31, 2022 | 187 | 14 | 8.09% |
| Dec 31, 2021 | 173 | 62 | 55.86% |
| Dec 31, 2020 | 111 | 18 | 19.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FBIO News
- 14 days ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 15 days ago - Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 22 days ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 23 days ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 5 weeks ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire